Bevacizumab plus lomustine significantly improves progression-free survival in recurrent or refractory glioblastoma
Bevacizumab Plus Lomustine Shows Potential for Glioblastoma Patients
This systematic review and network meta-analysis of randomized trials evaluated various treatments for recurrent or refractory glioblastoma.…
A combination of bevacizumab and lomustine showed a significant improvement in progression-free survival for adults with recurrent glioblast…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion
Eye Drug Comparison Shows Similar Vision Gains
This meta-analysis of 759 patients with RVO-ME found no significant difference between intravitreal ranibizumab and bevacizumab monotherapy …
Two common eye injections work equally well for swelling caused by retinal vein blockage, a new analysis finds.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
Carbonic anhydrase inhibitors and DEXi show superior CMT reduction in retinitis pigmentosa macular oedema
New Analysis Compares Treatments for Retinitis Pigmentosa Macular Oedema
This network meta-analysis evaluates various treatments for retinitis pigmentosa (RP)-associated macular oedema. The study found that carbon…
Different medications show varying success in reducing swelling and improving vision for patients with retinitis pigmentosa-associated macul…
Neoadjuvant chemotherapy with angiogenesis inhibitors increases pathological complete response rates in triple-negative breast cancer
Bevacizumab May Improve Pathological Response in Early Breast Cancer
This systematic review and meta-analysis of 10 RCTs involving 8,069 patients found that adding angiogenesis inhibitors to neoadjuvant chemot…
Adding an angiogenesis inhibitor to chemotherapy may improve response rates for certain types of early-stage breast cancer, especially tripl…
Multimodal strategies including bevacizumab and advanced radiotherapy techniques manage radiation-induced brain necrosis
New strategies help manage radiation-induced brain tissue damage
This narrative review synthesizes the pathogenesis, prevention, and treatment of radiation-induced brain necrosis (RBN) in patients with int…
Doctors are identifying new ways to prevent and treat brain tissue death caused by radiation during head and neck cancer treatments.
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
Adding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer
This systematic review and meta-analysis of phase II and III trials evaluated angiogenesis inhibitors combined with chemotherapy versus chem…
A large review of eight thousand four hundred patients found that adding angiogenesis inhibitors to standard chemotherapy improved how long …
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…